Antiviral efficacy of cerium oxide nanoparticles.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
05 11 2022
Historique:
received: 17 05 2022
accepted: 31 10 2022
pubmed: 6 11 2022
medline: 9 11 2022
entrez: 6 11 2022
Statut: epublish

Résumé

Nanomaterials are prospective candidates for the elimination of viruses due to their multimodal mechanisms of action. Here, we tested the antiviral potential of a largely unexplored nanoparticle of cerium dioxide (CeO

Identifiants

pubmed: 36335167
doi: 10.1038/s41598-022-23465-6
pii: 10.1038/s41598-022-23465-6
pmc: PMC9637224
doi:

Substances chimiques

ceric oxide 619G5K328Y
Silicon Dioxide 7631-86-9
Antiviral Agents 0
Silver 3M4G523W1G
Cerium 30K4522N6T

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

18746

Subventions

Organisme : Eesti Teadusagentuur
ID : COVSG2
Organisme : Eesti Teadusagentuur
ID : PRG629
Organisme : Eesti Teadusagentuur
ID : PRG1496
Organisme : Tartu Ülikool
ID : PLTFYARENG53
Organisme : Sihtasutus Archimedes
ID : TK141

Informations de copyright

© 2022. The Author(s).

Références

Environ Sci Technol. 2009 Jun 15;43(12):4537-46
pubmed: 19603674
J Hyg (Lond). 1938 Nov;38(6):732-49
pubmed: 20475467
Nanotechnology. 2021 Jun 17;32(36):
pubmed: 34020439
Virulence. 2012 Jul 1;3(4):351-67
pubmed: 22722247
Appl Environ Microbiol. 2014 Apr;80(8):2343-50
pubmed: 24487537
Angew Chem Int Ed Engl. 2018 Jul 20;57(30):9408-9412
pubmed: 29862623
Biotechnol Bioeng. 2007 Dec 1;98(5):1083-93
pubmed: 17546691
Nanomedicine (Lond). 2021 Mar;16(6):497-516
pubmed: 33683164
Environ Sci Technol. 2010 Aug 15;44(16):6350-6
pubmed: 20704235
Int J Mol Sci. 2018 Jan 28;19(2):
pubmed: 29382085
J Virol. 2010 Nov;84(22):12011-7
pubmed: 20844030
ACS Nano. 2021 Sep 28;15(9):14544-14556
pubmed: 34436866
J Nanobiotechnology. 2017 Oct 3;15(1):65
pubmed: 28974225
Biochem Biophys Res Commun. 2020 Nov 26;533(1):195-200
pubmed: 32958250
J Nanobiotechnology. 2005 Jun 29;3:6
pubmed: 15987516
Environ Sci Technol. 2017 Aug 1;51(15):8692-8700
pubmed: 28657725
Chem Commun (Camb). 2005 Oct 28;(40):5059-61
pubmed: 16220170
J Nanobiotechnology. 2010 Jul 13;8:15
pubmed: 20626911
iScience. 2021 Feb 24;24(3):102226
pubmed: 33733075
Biochim Biophys Acta. 1981 Jul 27;654(2):249-55
pubmed: 6974569
Genetics. 1997 Nov;147(3):953-9
pubmed: 9383044
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 Sep;13(5):e1707
pubmed: 33638618
Cytotechnology. 2015 May;67(3):427-35
pubmed: 24643389
Mater Sci Eng C Mater Biol Appl. 2020 Jul;112:110924
pubmed: 32409074
Nanoscale Res Lett. 2013 Feb 20;8(1):93
pubmed: 23421446
Nanomedicine. 2017 Jan;13(1):219-230
pubmed: 27575283
Acc Chem Res. 2020 Aug 18;53(8):1545-1556
pubmed: 32667182
ACS Nano. 2008 Oct 28;2(10):2121-34
pubmed: 19206459
Biomed Res Int. 2018 Jan 23;2018:1923606
pubmed: 29607315
PeerJ. 2019 Feb 11;7:e6315
pubmed: 30775167
Int J Mol Sci. 2020 Mar 30;21(7):
pubmed: 32235542
Environ Sci Technol. 2006 Oct 1;40(19):6151-6
pubmed: 17051814
Ecotoxicol Environ Saf. 2014 Mar;101:240-7
pubmed: 24507152
Int J Nanomedicine. 2013;8:4303-14
pubmed: 24235828
Infect Dis Clin North Am. 2010 Jun;24(2):413-37
pubmed: 20466277
Chempluschem. 2020 Aug 21;:
pubmed: 32881384
Nanomaterials (Basel). 2020 Aug 09;10(8):
pubmed: 32784939
J Nanobiotechnology. 2010 Jan 20;8:1
pubmed: 20145735
Nanomedicine (Lond). 2020 Feb;15(5):467-488
pubmed: 32063095
Front Pharmacol. 2021 Mar 08;12:632677
pubmed: 33762954
Environ Sci Technol. 2017 May 2;51(9):4944-4950
pubmed: 28333444
Nanomaterials (Basel). 2020 Aug 21;10(9):
pubmed: 32825737
Mikrobiol Z. 2010 May-Jun;72(3):42-7
pubmed: 20695228
J Nanosci Nanotechnol. 2016 Jul;16(7):7720-7730
pubmed: 27547159
Virus Res. 1987 Nov;8(4):363-71
pubmed: 2829461
Appl Environ Microbiol. 2020 Aug 18;86(17):
pubmed: 32591388
Biol Trace Elem Res. 2021 Aug;199(8):3159-3176
pubmed: 33029761
Foodborne Pathog Dis. 2010 Mar;7(3):319-26
pubmed: 19919284
Microb Pathog. 2021 Sep;158:105071
pubmed: 34182075
View (Beijing). 2020 Jun;1(2):e16
pubmed: 34766164
ACS Nano. 2011 Jun 28;5(6):4537-49
pubmed: 21612305
ACS Appl Mater Interfaces. 2021 Jan 13;13(1):2033-2043
pubmed: 33378149
BMC Cancer. 2016 Mar 15;16:220
pubmed: 26979107
Sci Rep. 2020 Dec 29;10(1):22419
pubmed: 33376251

Auteurs

Alexandra Nefedova (A)

Institute of Physics, University of Tartu, W. Ostwaldi Street 1, 50411, Tartu, Estonia.

Kai Rausalu (K)

Institute of Technology, University of Tartu, Nooruse Street 1, 50411, Tartu, Estonia.

Eva Zusinaite (E)

Institute of Technology, University of Tartu, Nooruse Street 1, 50411, Tartu, Estonia.

Alexander Vanetsev (A)

Institute of Physics, University of Tartu, W. Ostwaldi Street 1, 50411, Tartu, Estonia.

Merilin Rosenberg (M)

Institute of Molecular and Cell Biology, University of Tartu, Riia Street 23, 51010, Tartu, Estonia.
Department of Chemistry and Biotechnology, Tallinn University of Technology, Akadeemia Street 15, 12618, Tallinn, Estonia.

Kairi Koppel (K)

Institute of Molecular and Cell Biology, University of Tartu, Riia Street 23, 51010, Tartu, Estonia.

Stevin Lilla (S)

Institute of Physics, University of Tartu, W. Ostwaldi Street 1, 50411, Tartu, Estonia.

Meeri Visnapuu (M)

Institute of Physics, University of Tartu, W. Ostwaldi Street 1, 50411, Tartu, Estonia.

Krisjanis Smits (K)

Institute of Solid State Physics, University of Latvia, Kengaraga Street 8, Riga, 1063, Latvia.

Vambola Kisand (V)

Institute of Physics, University of Tartu, W. Ostwaldi Street 1, 50411, Tartu, Estonia.

Tanel Tätte (T)

Institute of Physics, University of Tartu, W. Ostwaldi Street 1, 50411, Tartu, Estonia.

Angela Ivask (A)

Institute of Molecular and Cell Biology, University of Tartu, Riia Street 23, 51010, Tartu, Estonia. angela.ivask@ut.ee.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH